C H Meyer1, S Mennel, N Eter. 1. Augenklinik, Universität Bonn, Ernst-Abbe-Strasse 2, 53127, Bonn. carsten_h.meyer@ukb.uni-bonn.de
Abstract
BACKGROUND: Intravitreal injection of vascular endothelial growth factor inhibitors is safe as a standardized procedure. In a retrospective study, we examined the incidence of intraocular inflammation and endophthalmitis when intravitreal Avastin was given on both an outpatient and an inpatient basis. METHODS AND PATIENTS: Two centers treated a total of 1844 patients with intravitreal Avastin injection (IVA), 1.25 mg/0.05 ml. The medication was given under aseptic conditions with a sterile drape and lid speculum and after an incubation of 5% povidone-iodine for 60 s in the conjunctival fornix. Center A performed all applications as an outpatient procedure with no postoperative topical antibiotics. Center B performed all IVAs prior to a 1-day hospital admission and gave topical antibiotics for 3 days. In both centers the patients were told to return to the hospital immediately if visual disturbance, pain, or redness of the eyes was noticed. RESULTS: Center A did 984 IVAs. Postoperatively no patients had endophthalmitis. On the 2nd postoperative day, two patients developed a mild intraocular uveitis, which was treated with local steroid ointments. Center B did 860 IVAs. Five days after discharge from the hospital, two patients presented with endophthalmitis and underwent vitrectomy when their vision dropped to counting fingers. There was no positive microbiological result of either vitreous probe. CONCLUSIONS: Although equal treatment guidelines were established, the perioperative hospital admission and postoperative application of topical antibiotic ointment could not reduce the occurrence of mild to severe intraocular endophthalmitis.
BACKGROUND: Intravitreal injection of vascular endothelial growth factor inhibitors is safe as a standardized procedure. In a retrospective study, we examined the incidence of intraocular inflammation and endophthalmitis when intravitreal Avastin was given on both an outpatient and an inpatient basis. METHODS AND PATIENTS: Two centers treated a total of 1844 patients with intravitreal Avastin injection (IVA), 1.25 mg/0.05 ml. The medication was given under aseptic conditions with a sterile drape and lid speculum and after an incubation of 5% povidone-iodine for 60 s in the conjunctival fornix. Center A performed all applications as an outpatient procedure with no postoperative topical antibiotics. Center B performed all IVAs prior to a 1-day hospital admission and gave topical antibiotics for 3 days. In both centers the patients were told to return to the hospital immediately if visual disturbance, pain, or redness of the eyes was noticed. RESULTS: Center A did 984 IVAs. Postoperatively no patients had endophthalmitis. On the 2nd postoperative day, two patients developed a mild intraocular uveitis, which was treated with local steroid ointments. Center B did 860 IVAs. Five days after discharge from the hospital, two patients presented with endophthalmitis and underwent vitrectomy when their vision dropped to counting fingers. There was no positive microbiological result of either vitreous probe. CONCLUSIONS: Although equal treatment guidelines were established, the perioperative hospital admission and postoperative application of topical antibiotic ointment could not reduce the occurrence of mild to severe intraocular endophthalmitis.
Authors: Donald J D'Amico; H N Masonson; Manju Patel; A P Adamis; E T Cunningham; D R Guyer; B Katz Journal: Ophthalmology Date: 2006-04-27 Impact factor: 12.079
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Jost B Jonas; Ulrich H Spandau; Florian Rensch; Stefan Von Baltz; Frank Schlichtenbrede Journal: J Ocul Pharmacol Ther Date: 2007-06 Impact factor: 2.671
Authors: A W Ferguson; J A Scott; J McGavigan; R A Elton; J McLean; U Schmidt; R Kelkar; B Dhillon Journal: Br J Ophthalmol Date: 2003-02 Impact factor: 4.638
Authors: J C Gines; M M Nentwich; A H Peggy Bedoya; P Cibils; A Esteche; F Laspina; M Samudio; N Fariña; H M de Kaspar Journal: Ophthalmologe Date: 2012-08 Impact factor: 1.059
Authors: Abdhish R Bhavsar; Joseph M Googe; Cynthia R Stockdale; Neil M Bressler; Alexander J Brucker; Michael J Elman; Adam R Glassman Journal: Arch Ophthalmol Date: 2009-12
Authors: Saloomeh Saati; Rajat N Agrawal; Stan Louie; Gerald J Chader; Mark S Humayun Journal: Graefes Arch Clin Exp Ophthalmol Date: 2009-07-31 Impact factor: 3.117
Authors: K Schmitz; M Maier; C R Clemens; F Höhn; J Wachtlin; F Lehmann; T Bertelmann; K Rüdiger; M Horn; A Bezatis; G Spital; C H Meyer Journal: Ophthalmologe Date: 2014-01 Impact factor: 1.059